• Login
    View Item 
    •   Home
    • Colleges & Programs
    • Medical College of Georgia (MCG)
    • Department of Neurology
    • Department of Neurology: Faculty Research and Presentations
    • View Item
    •   Home
    • Colleges & Programs
    • Medical College of Georgia (MCG)
    • Department of Neurology
    • Department of Neurology: Faculty Research and Presentations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Scholarly CommonsCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    About

    AboutCreative CommonsAugusta University LibrariesUSG Copyright Policy

    Statistics

    Display statistics

    Rivastigmine for the treatment of dementia associated with Parkinson's disease.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    NDT-3-775.pdf
    Size:
    87.84Kb
    Format:
    PDF
    Download
    Authors
    Reingold, Jennifer L
    Morgan, John C
    Sethi, Kapil D
    Issue Date
    2009-03-20
    URI
    http://hdl.handle.net/10675.2/139
    
    Metadata
    Show full item record
    Abstract
    Parkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD.This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.
    Citation
    Neuropsychiatr Dis Treat. 2007 Dec; 3(6):775-783
    Collections
    Department of Neurology: Faculty Research and Presentations

    entitlement

    Related articles

    • Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    • Authors: Rolinski M, Fox C, Maidment I, McShane R
    • Issue date: 2012 Mar 14
    • Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    • Authors: Jellinger KA
    • Issue date: 2018 Apr
    • Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    • Authors: Jellinger KA, Korczyn AD
    • Issue date: 2018 Mar 6
    • Cholinesterase inhibitors for Parkinson's disease dementia.
    • Authors: Maidment I, Fox C, Boustani M
    • Issue date: 2006 Jan 25
    • Rivastigmine and Parkinson dementia complex.
    • Authors: Moretti R, Torre P, Vilotti C, Antonello RM, Pizzolato G
    • Issue date: 2007 Apr
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.